⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10860665 | 0.74 | HSD17B10 (0.53) | — | |
| SCHEMBL2524462 | 0.73 | CGAS (0.47) | — | |
| SCHEMBL17501768 | 0.73 | — | — | |
| Water SCHEMBL6788837 | 0.70 | CGAS (0.44) | — | |
| SCHEMBL5006369 | 0.67 | CGAS (0.42) | — | |
| SCHEMBL25306527 | 0.66 | ALDH1A1 (0.40) | — | |
| SCHEMBL10765607 | 0.66 | CGAS (0.41) | — | |
| SCHEMBL9815359 | 0.63 | CGAS (0.46) | — | |
| SCHEMBL3691794 | 0.62 | — | — | |
| SCHEMBL3086461 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-10130642-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180050052-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9724359-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-9334245-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2675795-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20140364603-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8853427-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2675795-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Theravance, Inc. (US) | 2013-12-25 | — | — | EP | disclosed |
| CN-103380119-A | Substituted aminobutyric acid derivatives as enkephalinase inhibitors | THERAVANCE INC | 2013-10-30 | — | — | CN | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20130261316-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8481044-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120213806-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2012112742-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | WO | disclosed |